ABL1 and acute lymphoblastic leukemia: Finally, ALL xenografts have been used to study targeted therapies in high-risk ALL subtypes, including BCL2 inhibitors in hypodiploid ALL, JAK/STAT inhibitors in early T-cell precursor (ETP) ALL, and ABL-kinase inhibitors in Ph-like ALL49,95,96.